Maichael Talaat1,2, Kévin Premat3, Stéphanie Lenck3, Eimad Shotar3, Anne-Laure Boch4, Awad Bessar2, Mohammed Taema2, Farouk Hassan5, Tamer S Elserafy6, Vincent Degos7, Nader Sourour3, Frédéric Clarençon8,9. 1. Department of Interventional Neuroradiology, GRC BioFast, Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, 75013, Paris, France. 2. Department of Radiodiagnosis, Faculty of Medicine, Zagazig University E44519, Zagazig, Egypt. 3. Department of Interventional Neuroradiology, Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, 47-83 Boulevard de l'Hôpital 75013, Paris, France. 4. Department of Neurosurgery, Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, 75013, Paris, France. 5. Department of Radiodiagnosis, Faculty of Medicine, Cairo University, Cairo, C12613, Egypt. 6. Department of Neurology, Faculty of Medicine, Zagazig University, Zagazig, E44519, Egypt. 7. Department of Anesthesiology and Critical Care, Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, 75013, Paris, France. 8. Department of Interventional Neuroradiology, GRC BioFast, Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, 75013, Paris, France. frederic.clarencon@aphp.fr. 9. Department of Interventional Neuroradiology, Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, 47-83 Boulevard de l'Hôpital 75013, Paris, France. frederic.clarencon@aphp.fr.
Abstract
PURPOSE: To assess the obliteration rate, functional outcome, hemorrhagic complication, and mortality rates of exclusion treatment of low-grade brain arteriovenous malformations (BAVMs) (Spetzler and Martin grades (SMGs) 1 and 2), either ruptured or unruptured. METHODS: Electronic databases-Ovid MEDLINE and PubMed-were searched for studies in which there was evidence of exclusion treatment of low-grade BAVMs treated either by endovascular, surgical, radiosurgical, or multimodality treatment. The primary outcome of interest was angiographic obliteration post-treatment and at follow-up. The secondary outcomes of interest were functional outcome (mRS), mortality rate, and hemorrhagic complication. Descriptive statistics were used to calculate rates and means. RESULTS: Eleven studies involving 1809 patients with low-grade BAVMs were included. Among these, 1790 patients treated by either endovascular, surgical, radiosurgical, or multimodality treatment were included in this analysis. Seventy-two percent of BAVMs were Spetzler-Martin grade II. The overall (i.e., including all exclusion treatment modalities) complete obliteration rate ranged from 36.5 to 100%. The overall symptomatic hemorrhagic complication rate ranged from 0 to 7.3%; procedure-related mortality ranged from 0 to 4.7%. CONCLUSION: Our systematic review of the literature reveals a high overall obliteration rate for low-grade BAVMs, either ruptured or unruptured, with low mortality rate and an acceptable post-treatment hemorrhagic complication rate. These results suggest that exclusion treatment of low-grade BAVMs may be safe and effective, regardless of the treatment modality chosen.
PURPOSE: To assess the obliteration rate, functional outcome, hemorrhagic complication, and mortality rates of exclusion treatment of low-grade brain arteriovenous malformations (BAVMs) (Spetzler and Martin grades (SMGs) 1 and 2), either ruptured or unruptured. METHODS: Electronic databases-Ovid MEDLINE and PubMed-were searched for studies in which there was evidence of exclusion treatment of low-grade BAVMs treated either by endovascular, surgical, radiosurgical, or multimodality treatment. The primary outcome of interest was angiographic obliteration post-treatment and at follow-up. The secondary outcomes of interest were functional outcome (mRS), mortality rate, and hemorrhagic complication. Descriptive statistics were used to calculate rates and means. RESULTS: Eleven studies involving 1809 patients with low-grade BAVMs were included. Among these, 1790 patients treated by either endovascular, surgical, radiosurgical, or multimodality treatment were included in this analysis. Seventy-two percent of BAVMs were Spetzler-Martin grade II. The overall (i.e., including all exclusion treatment modalities) complete obliteration rate ranged from 36.5 to 100%. The overall symptomatic hemorrhagic complication rate ranged from 0 to 7.3%; procedure-related mortality ranged from 0 to 4.7%. CONCLUSION: Our systematic review of the literature reveals a high overall obliteration rate for low-grade BAVMs, either ruptured or unruptured, with low mortality rate and an acceptable post-treatment hemorrhagic complication rate. These results suggest that exclusion treatment of low-grade BAVMs may be safe and effective, regardless of the treatment modality chosen.
Authors: Alice L Hung; Wuyang Yang; Erick M Westbroek; Tomas Garzon-Muvdi; Justin M Caplan; Maria Braileanu; Joanna Y Wang; Geoffrey P Colby; Alexander L Coon; Rafael J Tamargo; Judy Huang Journal: Neurosurgery Date: 2017-09-01 Impact factor: 4.654
Authors: H Baharvahdat; R Blanc; R Fahed; S Smajda; G Ciccio; J-P Desilles; H Redjem; S Escalard; M Mazighi; D Chauvet; T Robert; P Sasannejad; M Piotin Journal: AJNR Am J Neuroradiol Date: 2019-02-21 Impact factor: 3.825
Authors: Matthew B Potts; Darryl Lau; Adib A Abla; Helen Kim; William L Young; Michael T Lawton Journal: J Neurosurg Date: 2015-02-06 Impact factor: 5.115
Authors: Andrew Nataraj; M Bahgaat Mohamed; Anil Gholkar; Ramon Vivar; Laurence Watkins; Robert Aspoas; Barbara Gregson; Patrick Mitchell; A David Mendelow Journal: World Neurosurg Date: 2013-02-20 Impact factor: 2.104
Authors: J P Mohr; Jessica R Overbey; Ruediger von Kummer; Marco A Stefani; Richard Libman; Christian Stapf; Michael K Parides; John Pile-Spellman; Ellen Moquete; Claudia S Moy; Eric Vicaut; Alan J Moskowitz; Kirsty Harkness; Charlotte Cordonnier; Alessandra Biondi; Emmanuel Houdart; Joachim Berkefeld; Catharina J M Klijn; Xavier Barreau; Helen Kim; Andreas Hartmann Journal: Neurology Date: 2017-09-06 Impact factor: 9.910
Authors: Brent C Morel; Blake Wittenberg; Jessa E Hoffman; David E Case; Zach Folzenlogen; Christopher Roark; Joshua Seinfeld Journal: J Pers Med Date: 2022-05-30